Vivostat患者源性纤维蛋白封闭剂与氧化纤维素（速即纱）在多种外科手术中止血效果的比较。
A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures.
作者信息
Hanks J B, Kjaergard H K, Hollingsbee D A
机构信息
Department of Surgery, University of Virginia Health System, Charlotteville, VA, USA.
出版信息
Eur Surg Res. 2003 Sep-Oct;35(5):439-44. doi: 10.1159/000072229.
AIM
To evaluate the haemostatic properties of Vivostat patient-derived fibrin sealant in a broad range of surgical procedures.
METHOD
In a prospective, randomised, multicentre, clinical study, typical surgical wounds of 69 patients (cardiothoracic, general, obstetric and gynaecologic, and vascular), requiring intervention to control bleeding, were treated with either Vivostat-derived sealant (n = 35) or Surgicel (n = 34) as required and the time taken to arrest bleeding was assessed.
RESULTS
Compared with Surgicel, the mean time to haemostasis of Vivostat-derived sealant was significantly shorter (1.6 vs. 3.3 min, p < 0.0001) and more patients were successfully treated (i.e. no additional haemostatic measures required; 94 vs. 65%, p = 0.003).
CONCLUSION
Vivostat-derived sealant is a more reliable and rapidly effective surgical haemostat than Surgicel.
目的
评估Vivostat患者源纤维蛋白密封剂在广泛外科手术中的止血特性。
方法
在一项前瞻性、随机、多中心临床研究中，69例（心胸外科、普通外科、妇产科和血管外科）需要干预控制出血的典型手术伤口，根据需要分别用Vivostat源密封剂（n = 35）或外科用止血纱布（n = 34）进行治疗，并评估止血所需时间。
结果
与外科用止血纱布相比，Vivostat源密封剂的平均止血时间显著更短（1.6分钟对3.3分钟，p < 0.0001），且成功治疗的患者更多（即无需额外止血措施；94%对65%，p = 0.003）。
结论
Vivostat源密封剂是一种比外科用止血纱布更可靠、起效更快的手术止血剂。
Zotero 插件